Business Context and Reporting Period
This Form 8-K Current Report was filed by Seres Therapeutics, Inc. on March 18, 2020. The filing primarily discloses the entry into a material definitive agreement for an equity offering and updates to the company's risk factors regarding the COVID-19 pandemic.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial metric disclosed is the authorization of an "at the market" equity offering program with aggregate gross sales proceeds of up to $25,000,000.
- Equity Offering Cap: $25,000,000
- Sales Agent: Cowen and Company, LLC
- Commission Rate: Up to 3.0% of gross proceeds
- Trading Symbol: MCRB (Nasdaq Global Select Market)
Material Changes
The company entered into a Sales Agreement on March 18, 2020, to sell shares of its common stock through an "at the market" offering. This agreement is subject to a shelf registration statement on Form S-3 that became effective on the same date. Additionally, the company updated its risk factors to reflect the potential adverse impacts of the COVID-19 outbreak on its business operations.
Outlook, Risks, and Management Commentary
Management has identified significant risks associated with the COVID-19 pandemic that could severely impact the company's preclinical studies and clinical trials. Specific concerns include:
- Delays in patient enrollment and clinical site initiation.
- Diversion of healthcare resources and hospital staff away from clinical trials.
- Interruption of data monitoring and subject visits due to travel restrictions.
- Potential delays in FDA approval timelines.
- Supply chain disruptions from contract manufacturing organizations.
- Limitations on employee resources due to illness or safety concerns.
Furthermore, the company noted that stock price volatility resulting from the epidemic may create difficulties in raising capital or force sales on unfavorable terms.
Investor Verification Checklist
- Verify the actual volume of shares sold and proceeds generated under the $25 million "at the market" program in subsequent filings.
- Monitor updates on clinical trial timelines and patient enrollment rates for potential delays attributed to COVID-19.
- Review future cash burn rates and liquidity positions given the potential difficulty in raising capital during market volatility.
- Check for any material adverse changes that could trigger termination of the Sales Agreement with Cowen.